These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16227354)

  • 1. Following the TRAIL from hepatitis C virus and alcohol to fatty liver.
    Afford SC; Adams DH
    Gut; 2005 Nov; 54(11):1518-20. PubMed ID: 16227354
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake.
    Mundt B; Wirth T; Zender L; Waltemathe M; Trautwein C; Manns MP; Kühnel F; Kubicka S
    Gut; 2005 Nov; 54(11):1590-6. PubMed ID: 16227360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRAIL: Activation of ERK1/2 Protects Cells Against Apoptosis.
    Cremer M
    Cancer Invest; 2005; 23(7):651. PubMed ID: 16305993
    [No Abstract]   [Full Text] [Related]  

  • 4. Tumor necrosis factor-related apoptosis-inducing ligand pathway and its therapeutic implications.
    de Vries EG; Gietema JA; de Jong S
    Clin Cancer Res; 2006 Apr; 12(8):2390-3. PubMed ID: 16638843
    [No Abstract]   [Full Text] [Related]  

  • 5. A new TRAIL to therapy of hepatocellular carcinoma: blocking the proteasome.
    Anan A; Gores GJ
    Hepatology; 2005 Sep; 42(3):527-9. PubMed ID: 16116625
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents.
    Rowinsky EK
    J Clin Oncol; 2005 Dec; 23(36):9394-407. PubMed ID: 16361639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins.
    Mirandola P; Sponzilli I; Gobbi G; Marmiroli S; Rinaldi L; Binazzi R; Piccari GG; Ramazzotti G; Gaboardi GC; Cocco L; Vitale M
    Int J Oncol; 2006 Jan; 28(1):127-33. PubMed ID: 16327988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway.
    Wang X; Ju W; Renouard J; Aden J; Belinsky SA; Lin Y
    Cancer Res; 2006 Jan; 66(2):1089-95. PubMed ID: 16424045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNF-alpha-related apoptosis-inducing ligand decoy receptor DcR2 is targeted by androgen action in the rat ventral prostate.
    Vindrieux D; Réveiller M; Florin A; Blanchard C; Ruffion A; Devonec M; Benahmed M; Grataroli R
    J Cell Physiol; 2006 Mar; 206(3):709-17. PubMed ID: 16245307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The suicide in the thymus, a twisted trail.
    Green DR
    Nat Immunol; 2003 Mar; 4(3):207-8. PubMed ID: 12605225
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) regulates endothelial nitric oxide synthase (eNOS) activity and its localization within the human vein endothelial cells (HUVEC) in culture.
    Di Pietro R; Mariggiò MA; Guarnieri S; Sancilio S; Giardinelli A; Di Silvestre S; Consoli A; Zauli G; Pandolfi A
    J Cell Biochem; 2006 Mar; 97(4):782-94. PubMed ID: 16229016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The activation of ERK1/2 via a tyrosine kinase pathway attenuates trail-induced apoptosis in HeLa cells.
    Lee MW; Bach JH; Lee HJ; Lee DY; Joo WS; Kim YS; Park SC; Kim KY; Lee WB; Kim SS
    Cancer Invest; 2005; 23(7):586-92. PubMed ID: 16305985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
    Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAIL (CD253), a new member of the TNF superfamily.
    Song C; Jin B
    J Biol Regul Homeost Agents; 2005; 19(1-2):73-7. PubMed ID: 16178278
    [No Abstract]   [Full Text] [Related]  

  • 15. TRAIL activates acid sphingomyelinase via a redox mechanism and releases ceramide to trigger apoptosis.
    Dumitru CA; Gulbins E
    Oncogene; 2006 Sep; 25(41):5612-25. PubMed ID: 16636669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNF-related apoptosis-inducing ligand (TRAIL) and erythropoiesis: a role for PKC epsilon.
    Vitale M; Gobbi G; Mirandola P; Ponti C; Sponzilli I; Rinaldi L; Manzoli FA
    Eur J Histochem; 2006; 50(1):15-8. PubMed ID: 16584980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.
    MacFarlane M; Kohlhaas SL; Sutcliffe MJ; Dyer MJ; Cohen GM
    Cancer Res; 2005 Dec; 65(24):11265-70. PubMed ID: 16357130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology.
    Zauli G; Secchiero P
    Cytokine Growth Factor Rev; 2006 Aug; 17(4):245-57. PubMed ID: 16750931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correspondence re: C. G. Ferreira et al., Apoptosis: target of cancer therapy. Clin. Cancer Res., 8: 2024-2034, 2002.
    de Vries EG; de Hooge MN; Gietema JA; de Jong S
    Clin Cancer Res; 2003 Feb; 9(2):912; author reply 913. PubMed ID: 12576467
    [No Abstract]   [Full Text] [Related]  

  • 20. Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors.
    Wenger T; Mattern J; Penzel R; Gassler N; Haas TL; Sprick MR; Walczak H; Krammer PH; Debatin KM; Herr I
    Cell Death Differ; 2006 Oct; 13(10):1740-51. PubMed ID: 16470224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.